Drugs / LEISH-F2
last change Dec 2011 re-read 2 minutes ago

LEISH-F2

Protein / enzyme biologic

Developed for
cutaneous leishmaniasis
Investigated by
Access to Advanced Health Institute (AAHI)

Trials 2 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00982774 Apr 2009 → Apr 2011 cutaneous leishmaniasis Access to Advanced Health Institute (AAHI) Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01011309 Oct 2009 → May 2011 cutaneous leishmaniasis Access to Advanced Health Institute (AAHI) Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as LEISH-F2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01011309
1

NCT00982774

Modality Protein / enzyme biologic “LEISH-F2 protein” NCT00982774